Bismuth subsalicylate: History, chemistry, and safety

Reviews of Infectious Diseases

Volumn 12, Issue , 1990, Pages S3-S8

  Bierer, Douglas Ws ^a  

^a PROCTER AND GAMBLE COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISMUTH SALICYLATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; BIOAVAILABILITY; CHEMISTRY; CONFERENCE PAPER; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG HYDROLYSIS; DRUG SAFETY; DRUG USE; GASTROINTESTINAL DISEASE; HISTORY; HUMAN; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL;

ANIMAL; BISMUTH; GASTROINTESTINAL SYSTEM; HUMAN; INTESTINAL ABSORPTION; ORGANOMETALLIC COMPOUNDS; SALICYLATES;

EID: 0025101531     PISSN: 01620886     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/12.Supplement_1.S3     Document Type: Article

References (17)

1. Marks G., Beatty W.K. The precious metals of medicine. New York: Charles Scribner’s Sons, 1975
2. Chambers T.K. Practical lectures on the management of the digestion in disease. Lecture V on diarrhea. Lancet 1857; 2:185–7
3. Skoglund M.L., Watters K. Bismuth concentration at site of Campylobacter pylori colonization [abstract]. Gastroenterology 1988;94:A430
4. Feldman S., Chen S.-L., Pickering L.K., Cleary T.G., Ericsson C.D., Hulse M. Salicylate absorption from a bismuth subsalicylate preparation. Clin Phamacol Ther 1981;29:788–92
5. Levin R.A., Laughlin P.J. Pepto-Bismol and the detection of occult blood [project no. 195.09]. Norwich Pharmacal Co., 1973
6. Pickering L.K., Feldman S., Ericsson C.D., Cleary T.G. Absorption of salicylate and bismuth from a bismuth subsalicylate-containing compound (Pepto-Bismol). J Pediatr 1981;99:654–6
7. Dromgoole S.H., Furst D.E. Applied pharmacokinetics. San Francisco: Applied Therapeutics, Inc., 1982:493
8. DuPont H.L., Ericsson C.D., Johnson P.C., Bitsura J.M., DuPont M.W., de la Cabada F.J. Prevention of travelers’ diarrhea by the tablet formulation of bismuth subsalicylate. JAMA 1987;257:1347–50
9. Buge A., Supino-Viterbo V., Rancurel G., Pontes C. Epileptic phenomena in a bismuth toxic encephalopathy. J Neurol Neurosurg Psychiatry 1981;44:62–7
10. Galland M.C., Rodor F., Jouglard J. Bismuth et encephalopathie. Medecine et Hygiene 1979;37:2579–82
11. Burns R., Thomas D.W., Barron V.J. Reversible encephalopathy possibly associated with bismuth subgallate ingestion. Br Med J 1974;1:220–3
12. Martin-Bouyer G., Barin C., Beugnet A., Cordier J., Guerbois H. Intoxications par les sels de bismuth administr£s par voie orale [editorial]. Gastroenterol Clin Biol 1978;2:349–56
13. Hasking G.J., Duggin J.M. Encephalopathy from bismuth subsalicylate. Med J Aust 1982;2:167
14. Ross J.F., Sahenk Z., Hyser C., Mendell J.R., Alden C.L. Characterization of a murine model for human bismuth encephalopathy [letter]. Neurotoxicology 1988;9:581–6
15. Escourolle R., Bourden R., Galli A., Gade P., Jaudon M.C., Hauw J.J., Gray F. Étude neuropathologique et toxicologique de douze cas d’encéphalopathie bismuthique (EB). Rev Neurol 1977;133:153–63
16. Dumas J.L.R., Lechevalier B., Breteau M., Allain Y. Encéphalopathie bismuthique: répartition intra-cérébrale du bismuth: étude anatomique et toxicologique de 3 cas. Nouv Presse Med 1978;7:4021–5
17. Hillemand P., Padiere M., Laquais B., Bouvet P. Traitment bismuthique et bismuthemie. Semaine de l’Hȏpital de Paris 1977;53:1663–9